Your browser doesn't support javascript.
loading
Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
Mikuteit, Marie; Zschäbitz, Stefanie; Erlmeier, Maximilian; Autenrieth, Michael; Weichert, Wilko; Hartmann, Arndt; Steffens, Sandra; Erlmeier, Franziska.
Afiliação
  • Mikuteit M; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Zschäbitz S; Dean's Office - Curriculum Development, Hannover Medical School, Hannover, Germany.
  • Erlmeier M; Department of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Autenrieth M; Department of Urology, München Klinik Bogenhausen, Munich, Germany.
  • Weichert W; Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
  • Hartmann A; Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
  • Steffens S; Member of the German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Erlmeier F; Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Oncology ; 100(10): 536-541, 2022.
Article em En | MEDLINE | ID: mdl-35760058
ABSTRACT

BACKGROUND:

Overexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear.

AIM:

The aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC). MATERIAL AND

METHODS:

Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Gas6 expression by immunohistochemistry.

RESULTS:

Eighty-one chRCC patients were eligible for analysis; of these, 24 (29.6%) patients were positive for Gas6. No significant associations were found for Gas6 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6- compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors.

CONCLUSION:

In chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Peptídeos e Proteínas de Sinalização Intercelular / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Peptídeos e Proteínas de Sinalização Intercelular / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article